Renergen Shareholders Approve ASP Isotopes Acquisition

ASP Isotopes Inc., an advanced materials company listed on NASDAQ, announced the approval by shareholders of Renergen Limited for its proposed acquisition of the South African company. This merger, structured through a scheme of arrangement, received overwhelming endorsement with 99.80% of shareholder votes in favor. However, the deal is contingent on fulfilling various regulatory and third-party consents before the September 30, 2025 deadline. ASP Isotopes primarily focuses on producing isotopes for healthcare and technology, while Renergen operates in the helium and LNG sectors. This merger is anticipated to create a company that is a key player in critical materials used across many industries, notably increasing impact on the semiconductor and electronics sectors. Expected to be accretive to ASP Isotopes' financial metrics from 2026, the merger aims to achieve a forecasted EBITDA exceeding $300 million by 2030. The transaction builds upon strategic synergies, aligning with ASP Isotopes' goals of leveraging its enrichment technologies across isotopic, nuclear, and green energy applications.